Mode
Text Size
Log in / Sign up
N/A N=18 Randomized Single-blind Treatment

A Non-invasive Intervention (BreEStim) for Management of Phantom Limb Pain (PLP) After Limb Amputation (Experiment 3)

Pain Management

Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Average Change in Pain as Measured by the Visual Analog Scale (VAS) — 1.38; 0.93 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
BreEStim 240 (Device); EStim 240 (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
The University of Texas Health Science Center, Houston
Primary completion
Feb 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Average Change in Pain as Measured by the Visual Analog Scale (VAS)
1.38; 0.93
SECONDARY
Average Change in Sensation Threshold on Amputated Limb Measured by Electrical Sensation Detection Threshold (EST)
-0.22; -0.11
SECONDARY
Average Change in Pain Threshold on Amputated Limb Measured by Electrical Pain Detection Threshold (EPT)
3.69; 0.99

Summary

The purpose of this study is to compare the effectiveness of innovative intervention of breathing controlled electrical stimulation (BreEStim) and conventional electrical stimulation (EStim) in management of neuropathic phantom limb pain in patients after limb amputation after multiple sessions of treatment.

Eligibility Criteria

Inclusion Criteria

  • has phantom limb pain (PLP) after amputation of one limb, upper or lower limb;
  • has chronic pain, >3 months;
  • is stable on oral pain medications at least two weeks. (patients are allowed to continue their pain medications, i.e., no change in pain medications.)

Exclusion Criteria

  • currently adjusting oral pain medications for their PLP;
  • has pain, but not PLP (e.g., from inflammation at the incision wound of the residual limb);
  • has a pacemaker, or other metal and/or implanted devices;
  • has cognitive impairment from brain injury or are not able to follow commands, or to give consent;
  • has amputation in multiple limbs;
  • have asthma or other pulmonary diseases;
  • are not medically stable;
  • have preexisting psychiatric disorders;
  • alcohol or drug abuse;
  • have a history of seizures/Epilepsy, or taking benzodiazepines, anticonvulsants, and antidepressants.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04751526). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search